Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40(7):1122-5.Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid...
ABSTRACT This session will review the Appropriate Use Criteria for Amyloid PET Imaging published in 2013 by the Amyloid Imaging Task Force jointly supported by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Alzheimer's Association (AA) and discuss various clinical scenarios in ...
Three amyloid PET tracers are approved by the FDA: florbetapir, florbetaben, and flutametamol (22–24). Table2provides the criteria for a positive scan for each tracer. Scan interpretation is best done by radiologists or nuclear medicine specialists; training programs for amyloid PET interpretation ...
The Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate use criteria for amyloid PET as an important tool for increasing the certainty of a diagnosis of Alzheimer disease in specific patient populations. Here,...
Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging ...
Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimers Dement. 2013;9(4):e106-e109....
Reconsideration of appropriate use criteria for amyloid PET based on real‐world experiencesdoi:10.1002/alz.079430Park, Kee HyungShim, YongSooChoi, Seong HyeYoun, Young ChulYang, Dong WonKim, SangYunAlzheimer's & Dementia: The Journal of the Alzheimer's Association...
Updated Appropriate Use Criteria for Amyloid and Tau PETdoi:10.1002/alz.078912Rabinovici, Gil D.Knopman, David S.Arbizu, JavierBenzinger, Tammie L.S.Donohoe, KevinHansson, OskarHerscovitch, PeterKuo, PhillipLingler, Jennifer HMinoshima, Satoshi...
beta-amyloid-petappropriate use criteriaZusammenfassungJuengling, Freimut DankwartAllenbach, GillesBruehlmeier, MatthiasKlaeser, BerndWissmeyer, Michael PeterGaribotto, ValentinaFelbecker, AnsgarGeorgescu, DanUniv Bern Fac Med Murtenstr 11 CH-3008 Bern SwitzerlandNuclearmedicine...
Additionally, the concept of clinically isolated syndrome (CIS) includes patients experiencing their first clinical episode but not yet meeting all diagnostic criteria for definitive MS. However, CIS patients are highly likely to progress to the definite form of the disease over time [93]. Currently...